Uncategorized
Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia
SEATTLE--(BUSINESS WIRE)--Visus Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, today reported positive topline results from VIVID, the company’s Phase 2 study of three novel topical ophthalmic formulations under investigation for the treatment of presbyopia. All three investigational candidates studied in VIVID achieved the endpoint of three lines of improvement in binocular near vis